

## COMPREHENSIVE BENEFITS

# DE-RISKING & ADDING VALUE TO INNOVATION

### FOR ACADEMICS

- Validate scientific hypotheses
- Accelerate discovery transfer to the clinic
- Gateway to public-private collaborations

### FOR INDUSTRIALS

- De-risk innovation
- Leverage science and technology capabilities
- Gateway to the best targets in immunology research
- Eligibility to research tax credit

### FOR ALL

- Critical expertise & know-how in one site
- Privileged access to advanced technologies
- Project management matching industrial mindset
- Improved IP strategy


## ABOUT MIMABS

Partner of the Marseille Immunopole cluster, MI-mAbs is an innovative immunotechnology platform positioned at the interface of therapeutic target discoverers and developers from the biopharmaceutical industry. Prize-winner of the program « *investissements d'avenir* » 2011 in the « *Pre-industrial demonstrators* » category, MI-mAbs contributes to the growth of Marseille, a world leader in immune-based therapies, including immunotherapy antibodies.

[www.mimabs.org](http://www.mimabs.org)  
[contact@mimabs.org](mailto:contact@mimabs.org)  
[www.linkedin.com/company/mimabs](http://www.linkedin.com/company/mimabs)

### MI-mAbs

117 Avenue de Luminy - CS 10951  
F13288 Marseille Cedex 9  
FRANCE



**MI mAbs**  
ANTIBODIES  
FOR MEDICINE


**THE HIGHWAY  
TO A CANDIDATE ANTIBODY**



# A FULLY INTEGRATED PLATFORM FOR TARGET AND MAB VALIDATION



## TISSUE EXPRESSION PROFILE

IMMUNOHISTOCHEMISTRY



## ACCESS TO MODEL CELLS & MICE



CYTOTOXICITY, IMMUNE MODULATION, ADCC ACTIVITY EFFICACY (OVERALL SURVIVAL, BIOLUMINESCENCE, ...)  
IMMUNOMONITORING  
COMBINATION THERAPY  
PHARMACOKINETICS, SAFETY  
MOUSE MODEL DEVELOPMENT (WT, TRANSGENIC, KO/KO THROUGH CIPHE)



HYBRIDOMA GENERATION, CLONING IN OPTIMIZED MAMMALIAN EXPRESSION VECTORS, PRODUCTION IN RECOMBINANT SYSTEMS (CHO, HEK)

## IMMUNOTECHNOLOGY

HUMANISATION  
ANTIBODY-DRUG-CONJUGATES (ADC)  
BISPECIFIC ANTIBODIES (BI-ABS)  
(ACCES TO THE SITE COUPLING TECHNOLOGY BY INNATE PHARMA FOR RESEARCH PURPOSES)  
PURIFICATION



\* MAB delivery Technology, Specificity, Functionality, Productivity, Quality

\*\* GO NO GO Based on Activity, Efficacy and Safety